We were able to evaluate transcriptional repression in 49 LUAD and 29 LUSC tumors in the TRACERx421 cohort and in 13 LUAD, 27 LUSC and 34 ER+ breast cancers from the TCGA cohort. This evidence concerns the gene ESR1 and breast cancer.